
Adbiron 250mg Tablet
Salt Composition: Abiraterone Acetate
Expiry Date: 01/2028
Inclusive of all taxes
120 tablet(s) in a bottle
About The Product
PROSTATE CANCER
Description
Adbiron 250mg tablet is an anticancer medication used in the treatment of primarily prostate cancer in men. It contains Abiraterone Acetate as an active ingredient.
The medicine works by inhibiting the enzyme which is responsible for the growth of cancer cells in the body. Doctors mostly suggest this hormonal therapy, specifically a type of anti-androgen therapy, also used in chemotherapy drug a form of targeted therapy in the same category as protein kinase inhibitors.
Indication
Prostate cancer
Common side effects
- Adbiron 250mg tablet cause common as well as severe side effects, as it affects hormone level in the body, visit the doctor if the symptoms persist.
- Common side effects include: ● High blood pressure ● Urinary tract infection ● Edema (swelling) ● Vomiting ● Fatigue ● Anemia ● Hot flashes ● Headache ● Joint swelling
Dosage and duration
- Doctor prescription is necessary for using Adbiron 250mg tablet.
- The medication should be taken on an empty stomach, either one hour before or two hours after the meal.
- Take it on a daily basis without skipping a single dose to increase the effectiveness of the treatment.
- Taking it in the wrong way or taking too much can cause very serious side effects.
- Consult the doctor to determine the correct dose and duration suitable for the condition.
Mechanism of action
Adbiron 250mg tablet work by restrict the protein (enzyme) CYP17 which is responsible for the growth of abnormal cancer cells in the body and is important for the production of androgen like testosterone.
By reducing androgen production, the medicine helps slow the growth of prostate cancer that depends on testosterone.
Safety advice
FAQs
Adbiron 250mg tablet show common as well as severe side effects, including- Joint swelling, fatigue, nausea, urinary tract infection, diarrhea and high blood pressure, consult the healthcare provider if the symptoms persist.
Reference
• Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018).
Abiraterone acetate in the treatment of prostate cancer. Biomedicine & Pharmacotherapy, 101, 211-218. • Logothetis, C.
J., Efstathiou, E., Manuguid, F., & Kirkpatrick, P. (2011).
Abiraterone acetate. Nature Reviews Drug Discovery, 10(8), 573. • Scott, L.
J. (2017).
Abiraterone acetate: a review in metastatic castration-resistant prostrate cancer. Drugs, 77(14), 1565-1576. • Attard, G., Reid, A.
H., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., ... & de Bono, J.
S. (2009).
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of clinical oncology, 27(23), 3742-3748.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
